[Comment] Gastric cancer with peritoneal metastases: hype or hope for HIPEC? | ClinicLens
Gastric cancer remains a major cause of cancer mortality, and prognosis is particularly poor in individuals with peritoneal metastases.1,2 Although the integration of immunotherapy and targeted agents—such as trastuzumab or zolbetuximab—into systemic chemotherapy has improved sur
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.